Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Rex Fang & Innovation Equity Premium Income ETF (FEPI) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance

Rex Fang & Innovation Equity Premium Income ETFTrade
Vertex Pharmaceuticals IncorporatedTrade

Price performance (Past 24H)

Key statistics

Rex Fang & Innovation Equity Premium Income ETF vs Vertex Pharmaceuticals Incorporated — how do they compare? Rex Fang & Innovation Equity Premium Income ETF trades at $41.87, while Vertex Pharmaceuticals Incorporated trades at $529.5 (market cap $132.79B). The key difference: Vertex Pharmaceuticals Incorporated is trading nearer its 52-week high, Rex Fang & Innovation Equity Premium Income ETF nearer its low. Which is the better fit depends on your goals.

FEPIVRTX
Sector
Income / Options OverlayHealth
52-Week High
$49.54$529.65
52-Week Low
$37.98$376.62
Market Cap
$132.79B
Enterprise Value
$126.92B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Rex Fang & Innovation Equity Premium Income ETF

FEPI trades at $41.78, up 0.8% with a bullish technical signal from moving averages, though oscillators are neutral. The ETF provides a high yield through weekly dividends, recently transitioning to this frequency to enhance income compounding. Support and resistance are tightly clustered around $41-$42, indicating potential near-term consolidation.

Outlook: High income appeals but covered call strategy caps upside and risks NAV erosion in downturns. Opportunities include weekly cash flow for income-focused investors; risks involve concentrated tech exposure and market volatility. Analyst views are mixed, emphasizing accumulation on weakness.

Vertex Pharmaceuticals Incorporated

Vertex Pharmaceuticals (VRTX) trades at $496.07, up 2.49% on the day, with a bullish technical signal from moving averages and strong institutional support. The company reported Q2 2026 revenue of $3.3 billion, beating estimates, and raised its full-year sales outlook, driven by cystic fibrosis treatments and newer products like CASGEVY. Financials show robust profitability with a 35% net income margin and positive cash flow trends, though recent EPS results have been mixed.

Outlook remains positive with an 84% analyst buy rating and a $534.25 consensus price target, implying upside. Key risks include execution on new product launches and competitive pressures, but solid fundamentals and raised guidance support a constructive view for investors seeking growth in biopharma.

Returns comparison

Trailing returns across standard periods

About Rex Fang & Innovation Equity Premium Income ETF

FEPI provides exposure to top innovation stocks while generating monthly income. It uses a covered call strategy on high-volatility tech stocks to capture option premiums for investors.

Read more on FEPI

About Vertex Pharmaceuticals Incorporated

Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.

Read more on VRTX